对于处于缓解期或疾病活动度较低的银屑病关节炎患者，减少生物制剂和靶向合成改善病情抗风湿药（DMARDs）的剂量并停药。
Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.
作者信息
Ramsay Helen, Johnston Renea V, Cyril Sheila, Glennon Vanessa, Grobler Liesl, Burgess Deanne M, McKenzie Bayden J, Whittle Samuel L, Buchbinder Rachelle
机构信息
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia.
出版信息
Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD015880. doi: 10.1002/14651858.CD015880.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To determine the benefits and harms of dose reduction or discontinuation of biologic disease-modifying anti-rheumatic drugs or targeted synthetic disease-modifying anti-rheumatic drugs in adults with psoriatic arthritis who are in remission or a low disease activity state.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：确定在处于缓解期或低疾病活动状态的银屑病关节炎成年患者中，减少或停用生物性改善病情抗风湿药或靶向合成改善病情抗风湿药的益处和危害。
相似文献
1
Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.对于处于缓解期或疾病活动度较低的银屑病关节炎患者，减少生物制剂和靶向合成改善病情抗风湿药（DMARDs）的剂量并停药。
Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD015880. doi: 10.1002/14651858.CD015880.
2
Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.生物制剂在低疾病活动度银屑病关节炎患者中的逐渐减量和停药。
Drugs. 2018 Nov;78(16):1705-1715. doi: 10.1007/s40265-018-0994-3.
3
Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings).生物 DMARDs 在中轴型脊柱关节炎中的剂量调整和停药：叙事性综述（2023 SPARTAN 年会论文集）。
Curr Rheumatol Rep. 2024 May;26(5):155-163. doi: 10.1007/s11926-024-01137-w. Epub 2024 Feb 9.
4
Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.澳大利亚关于炎症性关节炎中生物制剂和靶向合成疾病修饰抗风湿药物逐渐减量的建议。
Intern Med J. 2022 Oct;52(10):1799-1805. doi: 10.1111/imj.15816.
5
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物（DMARD）治疗失败的类风湿关节炎患者：一项Cochrane系统评价和网状Meta分析（NMA）
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
6
Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.炎症性风湿病生物治疗停药后的疾病活动度。
Clin Rheumatol. 2014 Mar;33(3):329-33. doi: 10.1007/s10067-014-2508-3. Epub 2014 Feb 5.
7
Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.对传统改善病情抗风湿药物或非甾体抗炎药反应不足的银屑病关节炎患者使用生物制剂疗效的间接比较：一项荟萃分析。
Semin Arthritis Rheum. 2016 Feb;45(4):428-38. doi: 10.1016/j.semarthrit.2015.09.004. Epub 2015 Oct 3.
8
Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?在银屑病关节炎中，能否停用或逐渐减少传统的疾病修饰抗风湿药物？
Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S54-8. Epub 2013 Oct 4.
9
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
10
[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].[类风湿关节炎缓解期生物制剂的停用或减量策略]
Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1.
引用本文的文献
1
Professionals' perception on nutritional care of adult patients in comprehensive specialized hospitals of East Wollega Zone, Ethiopia.埃塞俄比亚东沃莱加区综合专科医院专业人员对成年患者营养护理的认知
BMC Nutr. 2025 Jan 30;11(1):25. doi: 10.1186/s40795-025-01000-w.
本文引用的文献
1
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group.启动对银屑病关节炎综合结局指标的评估：GRAPPA-OMERACT 工作组的 2022 年更新。
J Rheumatol. 2023 Nov;50(Suppl 2):53-57. doi: 10.3899/jrheum.2023-0530. Epub 2023 Jul 7.
2
Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.澳大利亚关于炎症性关节炎中生物制剂和靶向合成疾病修饰抗风湿药物逐渐减量的建议。
Intern Med J. 2022 Oct;52(10):1799-1805. doi: 10.1111/imj.15816.
3
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.靶向治疗银屑病关节炎的系统评价：短期关节、皮肤、附着点炎和指（趾）炎结局的比较综合分析。
RMD Open. 2022 Mar;8(1). doi: 10.1136/rmdopen-2021-002074.
4
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
5
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.EULAR 推荐的药物治疗银屑病关节炎管理：2019 年更新。
Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.
6
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.中文学术文献翻译
Ann Rheum Dis. 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163. Epub 2020 May 7.
7
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.生物制剂治疗银屑病关节炎的疗效和安全性：系统文献回顾和网络荟萃分析。
RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2019-001117.
8
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.靶向 DMARDs 在诱导治疗中治疗活动性银屑病关节炎的疗效和安全性比较：系统评价和网络荟萃分析。
Semin Arthritis Rheum. 2019 Dec;49(3):381-388. doi: 10.1016/j.semarthrit.2019.06.001. Epub 2019 Jun 10.
9
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.低疾病活动度类风湿关节炎患者中肿瘤坏死因子阻断剂的减量和停用策略
Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3.
10
Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network.澳大利亚和新西兰肌肉骨骼临床研究网络的早期发展。
Intern Med J. 2020 Jan;50(1):17-23. doi: 10.1111/imj.14191.
Zotero 插件